NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq: GALT), if they purchased the Company’s securities during the period between January 6, 2014 and July 28, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Nevada.
What You May Do
If you purchased shares of Galectin and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (firstname.lastname@example.org). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 29, 2014.
About the Lawsuit
Galectin and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.
On July 24, 2014, Emerging Growth Corp. issued a press release touting Galectin and stating that Galectin was "nipping at [the] heels" of its competitors. Then, on July 28, 2014, an article on SeekingAlpha.com claimed that Galectin had "strong ties to stock promoters" engaging in a misleading campaign aimed at boosting its stock price, and an article on TheStreet.com revealed that Emerging Growth was the investor relations and marketing company Galectin was paying for misleading promotional campaigns to entice investors to buy its stock.
On this news, the value of Galectin’s stock plummeted by 61%.
About Kahn Swick & Foti, LLC
To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.